Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.30 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6137571 | 0.74 | MAOB (0.40) | OPRK1 | |
| SCHEMBL6137564 | 0.74 | MAOB (0.40) | OPRK1 | |
| SCHEMBL6377017 | 0.72 | SLC16A3 (0.33) | PTGER4 | |
| SCHEMBL7655260 | 0.72 | SLC16A3 (0.33) | PTGER4 | |
| SCHEMBL9794051 | 0.71 | HTR2A (0.49) | OPRM1OPRK1 | |
| SCHEMBL9794039 | 0.71 | HTR2A (0.49) | OPRM1OPRK1 | |
| SCHEMBL662224 | 0.71 | AGXT (0.43) | — | |
| SCHEMBL11968991 | 0.69 | CA12 (0.50) | — | |
| SCHEMBL14588832 | 0.68 | PYCR1 (0.37) | — | |
| SCHEMBL12853146 | 0.68 | GABRA1 (0.42) | OPRM1OPRK1PTGER4PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9394273-B2 | Therapeutic prostaglandin receptor agonists | ALLERGAN, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150329518-A1 | THERAPEUTIC PROSTAGLANDIN RECEPTOR AGONISTS | ALLERGAN, INC. | 2015-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329518-A1 | THERAPEUTIC PROSTAGLANDIN RECEPTOR AGONISTS | PTGIR, PTGDR, PTGFR | OPRM1 443/4885OPRK1 260/4885PTGER4 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.